Paul Schimmel out Brandicourt in on BOD | ALNY Message Board Posts

Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34764 of 34830  at  2/27/2020 4:02:07 PM  by


Paul Schimmel out Brandicourt in on BOD


− Appoints Dr. Olivier Brandicourt, Former CEO of Sanofi and Global Pharmaceutical Industry Leader

− Announces Retirement of Dr. Paul Schimmel, an Alnylam Co-founder, After Nearly Eighteen Years of Service

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc.(ALNY) , the leading RNAi therapeutics company, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors effective March 2, 2020. Dr. Brandicourt served as Chief Executive Officer and a member of the Board of Directors of Sanofi from 2015 to 2019. Prior to that he was CEO and chair of Bayer HealthCare from 2013 to 2015, and spent 13 years at Pfizer, including as a member of its Executive Leadership Team and President and General Manager of the Emerging Markets and Established Products business units, amongst other roles.

In addition, Alnylam announces today the retirement of Dr. Paul Schimmel from the Board effective upon the conclusion of his current term at the Annual Meeting of Alnylam stockholders in 2020. Dr. Schimmel, Hahn Professor of Molecular Medicine at Scripps Research and MacArthur Professor Emeritus at MIT, is also a member of the National Academy of Sciences, National Academy of Medicine, American Philosophical Society, and American Academy of Arts and Sciences. Schimmel co-founded Alnylam where he served on the Board of Directors and Scientific Advisory Board since the Company’s founding in 2002. Following his retirement from the Board of Directors, Dr. Schimmel will continue to serve on the Company’s Scientific Advisory Board.

“We are honored to welcome Olivier to our Board of Directors at this exciting point in Alnylam’s history. Olivier’s past leadership in three leading pharmaceutical companies and extensive global commercial experience will provide invaluable perspective to our Board as Alnylam continues to launch ONPATTRO, introduces GIVLAARI around the world, and advances additional late-stage development programs on the path to financial self-sustainability,” said John Maraganore, Ph.D. Chief Executive Officer of Alnylam. “We very much look forward to the experience Olivier will bring as we continue to advance innovative RNAi therapeutics intended to transform the lives of patients with serious, and often highly debilitating, conditions.”

“I’m very pleased to become a director of Alnylam whose science and innovation I have long admired. Alnylam is at an exciting stage as a multi-product, global commercial company that is well positioned to deliver high impact for patients and significant growth for shareholders,” said Dr. Olivier Brandicourt. “I look forward to working with the Board and management in building Alnylam for the future.”

A physician by training, Dr. Brandicourt holds an Advanced Degree in Cellular and Immunological Pathophysiology from Paris Descartes University. He worked at the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa. Dr. Brandicourt formerly served as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) Board, is an Honorary Fellow of the Royal College of Physicians in London, and is a Board member of the National Committee on United States-China Relations in New York. Since December 2019 Dr. Brandicourt has also served as a Senior Advisor at Blackstone.

“On behalf of the Board and the entire Alnylam team, I want to extend our profound thanks to Paul Schimmel for his nearly eighteen years of service with Alnylam, and the enormous contributions he has made to our continuing success,” said Dr. Maraganore. “In 2002, Paul and Alnylam’s other founders had the bold vision that the scientific breakthrough of RNAi could lead to the development of a whole new class of medicines. With the approvals of ONPATTRO and GIVLAARI, and the recently announced positive readouts from pivotal studies of inclisiran and lumasiran, Paul has contributed to a rare event in science and medicine to see that vision realized.”

“I am proud to have played a part in building this distinctive company from birth. The Alnylam journey has been nothing short of remarkable, from conquering the many scientific and business challenges to now bringing RNAi therapeutics to patients around the world,” said Paul Schimmel. “I also want to extend a warm welcome to Dr. Brandicourt whose experience and voice will be very beneficial as Alnylam continues its global commercialization efforts.”


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 93
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
34765 Re: Paul Schimmel out Brandicourt in on BOD - Endpoints Steve_382 0 2/28/2020 12:09:26 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by